This is a routine insider reporting obligation related to new hire equity grants. No immediate financial impact, but traders should monitor future Form 4 filings for actual option exercises or stock sales, which could signal insider sentiment.
Price Chart
Executive Summary
Justin J. McAnear, CFO of Alamar Biosciences, filed a Form 3 disclosing an initial grant of stock options to purchase 570,719 shares of Class B common stock at $4.62 per share, with a 10-year term expiring in 2035. The filing also includes a power of attorney appointing company executives to file Section 16 reports on his behalf.
Key Facts
- Justin J. McAnear, Chief Financial Officer, filed initial beneficial ownership report (Form 3) on April 16, 2026
- Option to purchase 570,719 shares of Class B Common Stock granted at $4.62 per share
- Options vest 25% on October 13, 2026, and 1/48th monthly thereafter, subject to continuous service
- Option expiration date is October 14, 2035
- Power of attorney granted to Timothy White, Mike Seater, and Jessie Wang to file Forms 3, 4, and 5 on McAnear's behalf
Financial Impact
Approximately 570,719 new potential shares upon full exercise, representing non-dilutive compensation expense over time
Risk Factors
- Potential future dilution if options are exercised
- Limited insight into overall capital structure or performance
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001786386-26-000004 |
| Document: 0001786386-26-000004-index-headers.html | 0001786386-26-000004 |
| Document: 0001786386-26-000004-index.html | 0001786386-26-000004 |
| Document: 0001786386-26-000004.txt | 0001786386-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (+10.83%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.39 (−5.80%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.39 (−7.35%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.39 (−0.33%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.39 (−16.90%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.39 (+10.91%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.39 (+6.93%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.39 (+26.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers